Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

THYROID DISEASE

Shining a light on thyroid eye disease

Effective medical treatment for thyroid eye disease, a debilitating condition that can cause sight loss, has been lacking. A recent phase III trial of teprotumumab, an IGF1R antagonist, reports encouraging results and could be a game changer. Here, the trial is put in the context of current management strategies to address this question.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Taylor, P. N. et al. Novel insights into the pathogenesis and non-surgical management of Graves orbitopathy. Nat. Rev. Endocrinol. 16, 104–116 (2020).

    Article  CAS  Google Scholar 

  2. Douglas, R. S. et al. Teprotumumab for the treatment of active thyroid eye disease. N. Engl. J. Med. 382, 341–52 (2020).

    Article  Google Scholar 

  3. Crudden, C. et al. Below the surface: IGF-1R therapeutic targeting and its endocytic journey. Cells 8, 1223–1245 (2019).

    Article  Google Scholar 

  4. Smith, T. J. & Janssen, J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr. Rev. 40, 236–267 (2018).

    Article  Google Scholar 

  5. Minich, W. B. et al. Autoantibodies to the IGF1 receptor in Graves’ orbitopathy. J. Clin. Endocrinol. Metab. 98, 752–760 (2013).

    Article  CAS  Google Scholar 

  6. Smith, T. J. et al. Teprotumumab for thyroid-associated ophthalmopathy. N. Engl. J. Med. 376, 1748–1761 (2017).

    Article  CAS  Google Scholar 

  7. Thornton, J., Kelly, S. P., Harrison, R. A. & Edwards, R. Cigarette smoking and thyroid eye disease: a systematic review. Eye 21, 1135–45 (2007).

    Article  CAS  Google Scholar 

  8. Krieger, C. C. et al. TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis. J. Clin. Endocrinol. Metab. 101, 2340–2347 (2016).

    Article  Google Scholar 

  9. Furmaniak, J. et al. OP-08-57 Blocking the TSH receptor with the human monoclonal autoantibody K1-70TM improves Graves’ ophthalmopathy and aids control of advanced follicular thyroid cancer — results of long-term treatment under the first in human single patient expanded use therapy. Eur. Thyroid J. 7, S22 (2018).

    Google Scholar 

  10. Bartalena, L. et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur. Thyroid J. 5, 9–26 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marian Ludgate.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ludgate, M. Shining a light on thyroid eye disease. Nat Rev Endocrinol 16, 259–260 (2020). https://doi.org/10.1038/s41574-020-0340-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-020-0340-1

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing